News & Articles

The addition of COVID-19 antibody tests to the portfolio aims to further support the pandemic response on multiple fronts

Learn how high-throughput, real-time cell analysis can accurately detect and quantify virus-neutralizing antibodies and see how this technology is advancing COVID-19 research

Access SARS-CoV-2 IgG assay shows excellent agreement with the Genscript Surrogate Virus Neutralization Test

Fluidigm COVID-19 campus safeguard program improves availability of non-invasive, saliva-based SARS-CoV-2 tests for higher education institutions

We speak with Dr. Ed Emmott, founder of The Emmott Lab & COVID-19 Mass Spec Coalition member, about his latest research into the disease

The collaboration will ensure GMP production of material for the Phase 1 clinical trial of Scancell’s DNA vaccine against SARS-CoV-2

A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients

Explore our roundup of key considerations for a successful CRISPR/Cas9 experiment

The Assure COVID-19 IgG/IgM Rapid Test Device was first authorized for emergency use by certain labs in July 2020

The Direct assay is validated on a wide range of specimen types, and can be run in parallel with the Simplexa Flu A/B & RSV Direct Gen II assay

cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus

The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity

Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, aims to provide accurate results in less than 15 minutes

New dye offers researchers improved brightness to resolve rare and low antigen density populations more easily

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination

Workflow is quick, simple and scalable for high-throughput antibody detection with high PPA sensitivity and NPA specificity

Supports cross-functional teams of chemists and biologists developing non-natural, chemically modified therapeutics for drug discovery